- Home
- HASI vs ACAD Comparison
HASI vs ACAD Comparison
Compare HASI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HASI
- ACAD
- Stock Information
- Founded
- HASI 1981
- ACAD 1993
- Country
- HASI United States
- ACAD United States
- Employees
- HASI N/A
- ACAD N/A
- Industry
- HASI Real Estate Investment Trusts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- HASI Real Estate
- ACAD Health Care
- Exchange
- HASI Nasdaq
- ACAD Nasdaq
- Market Cap
- HASI 3.4B
- ACAD 4.0B
- IPO Year
- HASI 2013
- ACAD 2004
- Fundamental
- Price
- HASI $28.79
- ACAD $25.74
- Analyst Decision
- HASI Strong Buy
- ACAD Buy
- Analyst Count
- HASI 8
- ACAD 20
- Target Price
- HASI $38.25
- ACAD $28.63
- AVG Volume (30 Days)
- HASI 1.2M
- ACAD 2.0M
- Earning Date
- HASI 08-07-2025
- ACAD 08-06-2025
- Dividend Yield
- HASI 5.83%
- ACAD N/A
- EPS Growth
- HASI N/A
- ACAD 615.00
- EPS
- HASI 1.59
- ACAD 1.33
- Revenue
- HASI $92,418,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- HASI $180.01
- ACAD $13.28
- Revenue Next Year
- HASI $14.84
- ACAD $10.88
- P/E Ratio
- HASI $18.14
- ACAD $18.70
- Revenue Growth
- HASI N/A
- ACAD 14.41
- 52 Week Low
- HASI $21.98
- ACAD $13.40
- 52 Week High
- HASI $36.56
- ACAD $25.88
- Technical
- Relative Strength Index (RSI)
- HASI 63.95
- ACAD 66.52
- Support Level
- HASI $27.34
- ACAD $24.47
- Resistance Level
- HASI $28.13
- ACAD $25.88
- Average True Range (ATR)
- HASI 0.86
- ACAD 0.71
- MACD
- HASI 0.27
- ACAD 0.00
- Stochastic Oscillator
- HASI 96.71
- ACAD 94.62
About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.